RT Journal Article
T1 Metallo-Liposomes of Ruthenium Used as Promising Vectors of Genetic Material.
A1 Lebrón, José Antonio
A1 Ostos, Francisco José
A1 López-López, Manuel
A1 Moyá, María Luisa
A1 Sales, Carlos
A1 García, Encarnación
A1 García-Calderón, Clara Beatriz
A1 García-Calderón, Margarita
A1 Peña-Gómez, María José
A1 Rosado, Iván V
A1 Balestra, Fernando R
A1 Huertas, Pablo
A1 López-Cornejo, Pilar
K1 gene therapy
K1 metallo-liposomes
K1 non-toxic nanocarriers
K1 ruthenium(II)-based lipids
K1 specificity by cancer cells
K1 transfection process
AB Gene therapy is a therapeutic process consisting of the transport of genetic material into cells. The design and preparation of novel carriers to transport DNA is an important research line in the medical field. Hybrid compounds such as metallo-liposomes, containing a mixture of lipids, were prepared and characterized. Cationic metal lipids derived from the [Ru(bpy)3]2+ complex, RuC11C11 or RuC19C19, both with different hydrophobic/lipophilic ratios, were mixed with the phospholipid DOPE. A relation between the size and the molar fraction α was found and a multidisciplinary study about the interaction between the metallo-liposomes and DNA was performed. The metallo-liposomes/DNA association was quantified and a relationship between Kapp and α was obtained. Techniques such as AFM, SEM, zeta potential, dynamic light scattering and agarose gel electrophoresis demonstrated the formation of lipoplexes and showed the structure of the liposomes. L/D values corresponding to the polynucleotide's condensation were estimated. In vitro assays proved the low cell toxicity of the metallo-liposomes, lower for normal cells than for cancer cell lines, and a good internalization into cells. The latter as well as the transfection measurements carried out with plasmid DNA pEGFP-C1 have demonstrated a good availability of the Ru(II)-based liposomes for being used as non-toxic nanovectors in gene therapy.
SN 1999-4923
YR 2020
FD 2020-05-25
LK https://hdl.handle.net/10668/28374
UL https://hdl.handle.net/10668/28374
LA en
DS RISalud
RD Apr 5, 2025